window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 24, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Phase 2 clinical trial

  • Cell & Gene Therapy,Clinical Trials,Rare Diseases,Regulatory Affairs

    First-in-class cell therapy for rare mitochondrial disorder gains FDA fast track

    FDA recognition accelerates development of first-in-class mitochondrial cell therapy for [...]

    July 4, 2025
Previous12

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Regeneron enters radiopharmaceuticals through multi-programme collaboration with Telix in oncology expansion
    Categories: Drug discovery, Oncology, Partnerships & Funding, Pharmaceuticals and therapeutics, Precision medicine, Research & Development, Technology and platforms
  • Pharma firms localise GLP-1 supply chains as shortages and geopolitical risks grow
    Categories: Biomanufacturing, CDMOs & Manufacturing, Drug Development, Manufacturing, Pharmaceuticals and therapeutics, Supply Chain & Logistics
  • Emalex wins US patent for ecopipam ODT as Tourette access program grows
    Categories: Clinical Development, Drug Development, FDA, Neurosciences, Pharmaceuticals and therapeutics, Rare Diseases
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top